The evolution of knowledge for treating Gram-negative bacterial infections.

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Gram-negative bacilli (GNB) infections have increased significantly since the mid-20th century, particularly with rising immunodeficiency and antibiotic use.
• Factors contributing to this rise include advances in anticancer therapy, surgery, corticosteroid use, and prosthetic materials, alongside better control of Gram-positive infections.
• GNB possess a unique double membrane, requiring specific antimicrobial agents capable of penetrating it for effective treatment.

Purpose of the Study:

• To review the evolving landscape of Gram-negative bacilli (GNB) infections.
• To analyze the historical and current antimicrobial treatments for GNB.
• To discuss the challenges and future directions in combating GNB infections.

Main Methods:

• Literature review of studies on Gram-negative bacilli (GNB) infections and antimicrobial therapies.
• Analysis of the historical efficacy and limitations of various antibiotic classes against GNB.
• Exploration of emerging therapeutic strategies and diagnostic advancements.

Main Results:

• Early antibiotics like sulphonamides and penicillin G showed limited efficacy against GNB.
• Beta-lactams, including ampicillin, expanded treatment options, but rising resistance necessitates exploring alternatives.
• Aminoglycosides, polymyxins, tetracyclines, and fluoroquinolones are current options, often requiring combination therapy for difficult-to-reach sites.
• Novel approaches like phage therapy combined with antibiotics are being investigated.

Conclusions:

• Future strategies must include narrower-spectrum immunosuppressants and antibiotics that preserve the human microbiota.
• Rapid diagnostic methods are essential for timely and targeted GNB infection management.
• A shift towards more precise and less disruptive antimicrobial interventions is needed to reduce the prevalence of GNB in infectious pathology.